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Poisoning by anti-malarial drugs 
David Tibbutta
Poisoning, deliberate or accidental, with drugs used to 
treat malaria, seems to be uncommon although data is not 
available from South Sudan. A study in Uganda suggested 
around 3% of  all cases of  poisoning admitted to hospital 
had taken chloroquine: no other anti-malarial drugs were 
involved [1].
The commonly used drugs used to treat malaria in 
South Sudan are artemether with lumefantrine (as “Co-
artem” or “Riamet”), artesunate and amodiaquine, quinine 
and occasionally doxycycline. Chloroquine is infrequently 
used because of  parasite resistance but nevertheless will 
be included in this review.
Chloroquine  and Quinine [2]
Chloroquine1 and quinine will be considered together 
as there are similarities in their toxic effects. Both drugs 
are quickly absorbed by the gastrointestinal tract and 
symptoms of  poisoning usually appear within three hours 
of  ingestion. 
The clinical features of  poisoning include:
Drowsiness, convulsions and coma•	  and
Hypotension•	  and cardiac dysrhythmias 
(especially ventricular tachycardia and fibrillation) 
leading to cardiac arrest. Ventricular dysrhythmias 
may be anticipated from changes on the 
electrocardiogram (ECG): inversion of  T-waves, 
prolongation of  QT interval and widening of  the 
QRS.
Respiratory failure.•	
Diplopia•	  (double vision), blurred vision, narrowing 
(constriction) of  the visual field (“tunnel” vision) 
and blindness.
The toxic effects on the cardiovascular system tend to 
be more severe from chloroquine than quinine. Toxicity 
on the eye (oculotoxicity) is the major problem from 
quinine poisoning.
The side effects of  pharmacological treatment with 
quinine are common and become exaggerated when the 
patient has taken a toxic dose:
Nausea•	  and vomiting,
Deafness•	  and tinnitus,
a david@tibbutt.co.uk  
1 Chloroquine is a 4-aminoquinolone and comes as a number of  salts 
mainly the phosphate and sulphate. 
Vasodilatation •	 (flushing sensation more obvious 
in a pale skin). This may be exacerbated by the 
vasodilatation caused by the malaria itself  and so 
cause postural (orthostatic) hypotension.
Abdominal pain•	  (especially epigastric) and
Visual impairment.•	
Hypoglycaemia•	  may result from stimulation of  
the pancreatic islet beta-cells. This is more common 
in pregnancy and infants. The risk is reduced by 
administering the quinine with glucose. However 
the nursing and medical staff  must be aware 
constantly of  the probability of  hypoglycaemia.
Thrombocytopenia•	  may result from an immune 
mechanism associated with quinine but this is 
rarely of  clinical importance. It may also be part 
of  the disseminated intravascular coagulation 
syndrome.
Rashes•	  and angio-oedema have been described. 
Itching without a rash is a recognised problem 
affecting a number of  Africans.
Confusional states•	  also occur but distinguishing 
malaria and quinine as the underlying cause is 
difficult.
Blackwater fever•	  (haemoglobinuria) is a serious 
complication.
Hypokalaemia•	  is very common with chloroquine 
poisoning: even though a facility for serum 
potassium assay is absent the hypokalaemia should 
be assumed.
The quantity of  chloroquine ingested is a useful 
predictor of  the likely symptoms and problems to expect 
[2] (see table 1).
The ingestion of  over 5 grams of  chloroquine and 
systolic hypotension (less than 80mmHg) almost always 
lead to a fatal result2. 
If  the plasma concentration of  quinine is less than 
10mg/L the symptoms are usually mild but if  greater than 
15mg/L the risk of  permanent visual damage and cardiac 
dysrhythmias is high.
Management of  poisoning
The priority is always to stabilise the poisoned patient 
with attention to the Airway, Breathing and Circulation. 
2 An electrocardiogram that shows a QRS duration of  >0.12 seconds 
is also a serious prognostic indicator.
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Ideally management should be carried out in an intensive 
care facility especially if  the patient is shocked with 
hypotension. Adequate hydration should be established. 
Mechanical ventilation may be needed with the added 
support of  very carefully titrated adrenaline [3] 
particularly if  there is chloroquine poisoning. Adrenaline 
may increase the risk of  cardiac dysrhythmias.
If  the ECG shows an intraventricular block then 
intravenous 250ml 8.4% sodium bicarbonate (i.e. 250 
mmol) is indicated.
Gastric lavage should be considered if  the patient 
arrives at the medical unit within one hour of  ingesting 
quinine or chloroquine. If  possible activated charcoal 
50 – 100G should then be given: this dose may need to 
be repeated every six hours depending on the clinical 
response.
There is no evidence that diazepam is cardiac 
protective. It is indicated for convulsions. 
Hypokalaemia may increase the risk of  cardiac 
dysrhythmias. It might be tempting to give routinely an 
intravenous infusion of  potassium. However during the 
recovery period severe “rebound” hyperkalaemia may 
develop. Therefore it is probably wise not to give extra 
potassium unless frequent serum potassium measurements 
can be made and the results immediately available.
artemether and Lumefantrine
These are usually used as a fixed-dose combination 
artemisinin-based combination treatment (each tablet 
contains 20 mg artemether and 120 mg lumefantrine) (e.g. 
“Co-artem”, “Riamet”).
Common side effects include cough, anorexia, nausea 
and vomiting, diarrhoea, palpitations, joint (arthralgia) and 
muscle pain (myalgia), headache, dizziness, lethargy and 
insomnia. The problem with many of  these symptoms is 
that they can be caused by the underlying malarial process. 
There are also a number of  rare but more severe adverse 
reactions: rash (including urticaria), oedema of  mouth and 
lips, dyspnoea and chest tightness, dysphagia, palpitations, 
fever, severe headaches and muscle weakness.  
Reported experience of  overdosage with this drug 
combination is sparse. The time after ingestion that 
each component reaches peak plasma concentration is 
different: for artemether it occurs at about 2 hours and 
for lumefantrine at about 6-8 hours. So this could have 
implications for the onset and duration of  toxic effects
The cardiac toxic effects are similar to those from 
chloroquine and in particular the prolonged QT-interval 
problem which may lead to serious irregular tachycardia. 
If  the patient is likely to have hypokalaemia then the risk 
of  this complication is increased. If  there is a history 
(or family history) of  a heart rhythm disorder or heart 
failure then this combination antimalarial is probably 
best avoided. The likelihood of  toxicity is increased by 
taking grapefruit juice as this raises the blood level of  
the drug. Anti-retrovirals may exacerbate the chance of  
a prolonged QT as will the use of  quinine or chloroquine 
after a course of  artemether - lumefantrine. There are 
many other drugs which may interfere with the effects of  
this artemether – lumefantrine combination and include 
amitriptyline, disopyramide, flecainide, procainamide, 
quinidine, sotalol, azole antifungals (e.g. fluconazole, 
ketoconazole), cisapride, clomipramine, fluoroquinolone 
antibiotics (e.g. ciprofloxacin), imipramine and macrolide 
antibiotics (e.g. clarithromycin) [4]. The effectiveness of  
hormonal contraceptives and women should be advised 
to use an alternative method.
Management of  poisoning
Given the similar toxic effects, especially the cardiac 
ones, to chloroquine and quinine the principles of  
management should be the same. The benefit of  gastric 
lavage is doubtful but the use of  activated charcoal should 
be considered.
Because of  the uncertainties of  the effects and outcome 
of  poisoning the patient must be observed carefully (pulse 
rate and rhythm and blood pressure) and for at least six 
hours after ingestion. If  possible the serum potassium 
should be measured looking for hypokalaemia. It is always 
wise to exclude hypoglycaemia. An ECG would indicate 
the development of  a prolonged QT interval and the risk 
of  dysrhythmias.
artesunate and amodiaquine
This is another artemisinin-based combination treatment 
(“Coarsucam”). Amodiaquine is a 4-aminoquinolone 
similar to chloroquine.
Many side effects have been described including 
weakness, headache, dizziness, anorexia, nausea, vomiting, 
abdominal pain, diarrhoea and an itchy rash [5].
Artesunate
As with other artemisinins toxic effects are infrequent 
Dose Ingested 
(grams) Severity Symptoms / signs
<2 Mild Visual / vomiting
2 - 3.5 Moderate Vomiting / visual
>3.5 - 4 Severe Cardiac toxicity / convulsions.
Table 1: The quantity of  chloroquine ingested and likely 
symptoms and signs
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[6]. More serious ones rarely noted include neutropenia, 
anaemia, haemolysis and hepatitis as indicated by raised 
liver enzymes.
Amodiaquine
There is a significant and potentially serious risk of  
neutropenia especially in children infected with HIV [7]. 
In addition cases of  hepatitis have been described. For 
this reason amodiaquine has been discontinued in some 
countries. However there appears to be little experience 
of  overdosage. Increased muscle tone, involuntary 
movements, convulsions and syncope have been 
described. Because of  its similarity to chloroquine the 
expected problems include 
Hypotension and cardiogenic shock.• 
Intraventricular conduction problems: the QRS • 
on ECG becomes widened and the QT interval 
prolonged.
Ventricular tachycardia and fibrillation.• 
Management of  poisoning
This is as for chloroquine, quinine and the artemether 
-  lumefantrine combination.
Doxycycline
Generally this is a non-toxic drug although nausea, 
vomiting and hypersensitivity reactions and rashes may 
occur. In most cases of  overdosage specific measures 
are not required and gastric lavage is unnecessary. In 
the unlikely event of  frequent or prolonged convulsions 
then treatment should be along conventional lines with 
oxygen and intravenous diazepam (10-20 mg in adults; 
0.1-0.3 mg/kg body weight in children) or lorazepam 
(4 mg in adults and 0.1 mg/kg in children). The blood 
sugar should be checked.
Learning points
Experience with managing the toxic effects of  1. 
antimalarial drugs is limited. However they are 
very widely used and the opportunities for self-
poisoning are great.
The potential for serious toxic effects exists 2. 
especially those affecting the cardiovascular 
system.
The availability of  cardiac monitoring is 3. 
widespread and hence clinical observation (pulse 
rate and rhythm, blood pressure, respiratory rate) 
is crucial.
All members of  the clinical team should know 4. 
about the “ABC” i.e. Airway, Breathing and 
Circulation.
The bed-side test for blood sugar is a simple 5. 
measurement and should never be forgotten as a 
possible cause of  a changed conscious level.
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Author’s comment
During my research for this review I was amazed to 
discover how little information seems to be available on 
experience with the toxic effects of  the combination drugs 
(ACT’s). This seems to me to be an excellent opportunity 
for colleagues in South Sudan to record any experience 
and report to this journal ... this could be an important 
contribution to medical science and practice.
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